Key result
Surgical risk as assessed by EuroSCORE II did not modify the treatment effect of revascularization in patients with ischemic LV dysfunction.
Why the study?
Does surgical risk stratification modify the treatment effect of revascularization in patients with ischemic LV dysfunction?
Does surgical risk stratification modify the treatment effect of revascularization in patients with ischemic LV dysfunction?
This editorial highlights that surgical risk scores do not explain the divergent outcomes between CABG and PCI trials in ischemic cardiomyopathy, underscoring the need for the upcoming STICH 3 trial.
Ischemic left ventricular (LV) systolic dysfunction in the setting of multivessel coronary artery disease presents a frequent and complex decision point in cardiovascular practice: Should the patient undergo coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI)? This decision is often guided by a combination of anatomical and clinical risk factors, with tools like the EuroSCORE intended to capture surgical risk. Yet, despite its centrality to care, the optimal revascularization strategy for these patients remains uncertain.
No takes yet. Share an insight, caveat, or question.
Redfors et al. (2025) conducted an editorial in Ischemic left ventricular systolic dysfunction and multivessel coronary artery disease. Revascularization (CABG or PCI) was evaluated. Surgical risk as assessed by EuroSCORE II did not modify the treatment effect of revascularization in patients with ischemic LV dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: